Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917953 | 0.90 | MEN1 (0.43) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL18095369 | 0.90 | MEN1 (0.37) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL14363514 | 0.89 | MEN1 (0.45) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL9732197 | 0.89 | MEN1 (0.45) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL10486622 | 0.89 | MEN1 (0.45) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL11669223 | 0.88 | — | — | |
| SCHEMBL21667954 | 0.88 | MEN1 (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL21668019 | 0.88 | MEN1 (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL16264036 | 0.88 | MEN1 (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL8459105 | 0.88 | MEN1 (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028364-A1 | CATIONIC CHROMENONES AND THEIR USE IN ONCOLOGY | FLORATEK PHARMA S A (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2024018017-A1 | CATIONIC CHROMENONES AND THEIR USE IN ONCOLOGY | Floratek Pharma SA (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070027182-A1 | Octahydroisoquinoline compounds as opioid receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2007014263-A2 | OCTAHYDROISOQUINOLINE COMPOUNDS AS OPIOID RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070010627-A1 | NEMATIC ELASTOMER FIBER WITH MECHANICAL PROPERTIES OF A MUSCLE | THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2007-01-11 | — | — | US | disclosed |
| US-7122598-B2 | Nematic elastomer fiber with mechanical properties of a muscle | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006023527-A1 | NEMATIC ELASTOMER FIBER WITH MECHANICAL PROPERTIES OF A MUSCLE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041061-A1 | Nematic elastomer fiber with mechanical properties of a muscle | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2006-02-23 | — | — | US | disclosed |
| US-6737124-B2 | ESPECIALLY DISILANES | DISPLAYTECH, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | KDM4C 2202/4885MEN1 2168/4885KMT2A 1473/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | KDM4C 2202/4885MEN1 2168/4885KMT2A 1473/4885 |
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | FFAR3, FFAR1, LPAR1 | KDM4C 2265/4885MEN1 3636/4885KMT2A 2566/4885 |
| US-20260028364-A1 | CATIONIC CHROMENONES AND THEIR USE IN ONCOLOGY | NR3C2, MC2R, NR3C1 | KDM4C 2567/4885MEN1 1350/4885KMT2A 3922/4885 |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | KDM4C 568/4885MEN1 4375/4885KMT2A 411/4885 |
| US-20070027182-A1 | Octahydroisoquinoline compounds as opioid receptor modulators | OPRL1, OPRM1, OPRK1 | KDM4C 1231/4885MEN1 4876/4885KMT2A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.